Genentech scraps $2B cell therapy pact
Genentech is continuing its summer of downsizing and cost-cutting, this time with plans to terminate a cell therapy…
Roche’s Chugai inks Swiss ADC deal potentially worth over $780M
Roche’s Chugai Pharmaceutical is starting off its centennial year by spending some Swiss cheese. The Japanese unit is…